Home pageInternational biotech eventsHighly Potent Active Pharmaceutical Ingredients (HPAPI)

Highly Potent Active Pharmaceutical Ingredients (HPAPI)

 

Holiday Inn, Kensington Forum, London, UK (May, 21 - 23, 2018)

 

About HPAPI

SMi is delighted to announce its 2nd Annual Highly Potent Active Pharmaceutical Ingredients conference coming to London on the 21st - 22nd May 2018.

The global market for Highly Potent Active Pharmaceutical Ingredients is currently on a growth fast track, largely driven by its major use in oncology for cancer treatment and more often in the form of ADCs. Over a quarter of drugs worldwide now contain HPAPIs, as they have proven to be more effective than other APIs.

However, working with APIs high in potency and cytotoxicity comes with many regulations and requirements, and presents pharmaceutical companies with challenges such as handling, containment, cost and security questions.

This conference will cover many important and in-demand aspects of the HPAPI industry, creating a networking platform for industry professionals and key players to share their knowledge and find new innovative solutions.

How Will You Benefit?

Network and learn from leading professionals such as:

CHAIR FOR 2018:

Justin Mason-Home, Director, HPAPI Project Services Limited

KEY SPEAKERS INCLUDE:

-          Ildikó Zeigler, Validation Expert, Gedeon Richter

-          Ulrich Ruemenapp, Head of Launch Preparation and Coordination, Bayer

-          Vincenzo De Sio, HPAPI Specialist, Cristália

-          Pascal Drago, Principal Technical Manager, Roche

-          Henri Motte, Head of Pilot Plant, UCB Pharma

-          Jeff Parry, Senior Scientist Manufacturability, AstraZeneca

-          Greg Sowell, Principal Scientific Manager, Genentech

FEATURED HIGHLIGHTS:

-          Discover practical approaches to HPAPI manufacturing in a controlled and efficient manner

-          Explore different containment methods and learn about which strategy best suits your needs

-          Evaluate the use of containment risk mitigation tools in early phase development

-          Learn how to manage and effectively and safely dispose of HPAPI, post-production waste

-          Discuss the most important regulations surrounding potent ingredients

View the full agenda: www.highlypotentapi.com/g2b

Early-Bird Rates

ü  BOOK BY 31ST JANUARY AND SAVE 400 GBP

ü  BOOK BY 28TH FEBRUARY AND SAVE 200 GBP

ü  BOOK BY 29TH MARCH AND SAVE 100 GBP

Additional Contact Info:

T: +44 (0)20 7827 6048

E: psolanki@smi-online.co.uk

OPPI, MPO, EU

We Recommend

Biosimilars USA
Biosimilars
Czech Bio

CEBIO

  • CEBIO
  • BC AV CR
  • Budvar
  • CAVD
  • CZBA
  • Eco Tend
  • Envisan Gem
  • Gentrend
  • JAIP
  • Jihočeská univerzita
  • Madeta
  • Forestina
  • ALIDEA

LinkedIn
TOPlist